Pharma R&D’s COVID-19 Scar
Executive Summary
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.